Dev Boodoosingh Casiano, MD
Pulmonary Disease · Ponce, PRNPI 1801098033
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,804 of the $9,967 with a category attached, or 68.3%. 25 manufacturers reported payments, led by Merck at 27.1% of the total.
Across 222 payments — averaging $44.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- AstraZeneca$2K
- GSK$1K
- Bayer$1K
- Jazz Pharmaceuticals Inc.$413
- Boehringer Ingelheim$392
- plus $2K from 19 others
What the payments were for
- Consulting fees$2,85029%
- Travel & lodging$160%
- Food & beverage$6,80468%
- Education$2983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 11 | $2,702 |
| AstraZeneca | 71 | $2,053 |
| GSK | 29 | $1,208 |
| Bayer | 21 | $1,109 |
| Jazz Pharmaceuticals Inc. | 13 | $413 |
| Boehringer Ingelheim | 11 | $392 |
| Actelion Pharmaceuticals US, Inc. | 3 | $209 |
| Mallinckrodt Hospital Products Inc. | 2 | $199 |
| Grifols USA, LLC | 1 | $177 |
| Harmony Biosciences LLC | 7 | $176 |
| Amgen | 3 | $167 |
| Olympus Latin America, Inc. | 3 | $166 |
| Sanofi | 8 | $153 |
| United Therapeutics Corporation | 2 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $133 |
| PBG Puerto Rico LLC | 6 | $115 |
| Viatris Specialty LLC | 3 | $87 |
| Mylan Specialty L.p. | 3 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Genentech USA, Inc. | 3 | $63 |
| Johnson & Johnson | 4 | $61 |
| Mylan LLC | 2 | $30 |
| Edwards Lifesciences | 1 | $29 |
| Shire North American Group Inc | 2 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$1,500
- Adempas$715
- NUCALA$368
- TEZSPIRE$250
- WINREVAIR$250
- FASENRA$245
- Prolastin-C$177
- AREXVY$125
- TYVASO$125
- EVIS EXERA II ULTRASOUND GASTROVIDEOSCOPE$118
- Tavneos$117
- TRELEGY ELLIPTA$104
How this compares
$9,967 in reported general payments places this provider in the 85th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 45 | $584,459 |
| AdempasRiociguat | 45 | $562,918 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 576 | $392,354 |
| OpsumitMacitentan | 12 | $151,927 |
| TezspireTezepelumab-Ekko | 30 | $133,984 |
| Spiriva RespimatTiotropium Bromide | 232 | $127,073 |
| XolairOmalizumab | 55 | $127,018 |
| Breo ElliptaFluticasone/Vilanterol | 255 | $110,952 |
| NucalaMepolizumab | 29 | $104,659 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 275 | $69,974 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 106 | $52,053 |
| Arnuity ElliptaFluticasone Furoate | 144 | $40,961 |
| SymbicortBudesonide/Formoterol Fumarate | 104 | $26,966 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $25,970 |
| Wixela InhubFluticasone Propion/Salmeterol | 95 | $20,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $392 | $763,585383 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta, Anoro Ellipta | $1,208 | $659,5311,026 claims |
| BayerAdempas | $1,109 | $562,91845 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere, Bevespi Aerosphere | $2,053 | $192,955188 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $209 | $151,92712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Ponce
- Domingo Chardon FelicianoPonce$45K
- George FahedPonce$16K
- Giovanni Veloz IrizarryPonce$11K
- Jesse Aleman-OrtizPonce$10K
- Keren Mendez RamirezPonce$8K
- Hector Puig-RamirezPonce$8K
- Sandra Galarza-VargasPonce$7K
- Ilean Lamboy HernandezPonce$5K
- Eugenio Rivera RiosPonce$3K
- Manuel Morell CataquetPonce$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.